Outcomes in Patients with Interstitial Lung Disease Receiving Programmed Cell Death Protein 1 (PD-1) Inhibitors

被引：0
|
作者：
Dobre, I. [1 ]
Frank, A. J. [2 ]
D'Silva, K. M. [2 ]
Okin, D. [2 ]
Sharma, A. [2 ]
Montesi, S. B. [2 ]
机构：
[1] Queens Univ, Sch Med, Kingston, ON, Canada
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7795
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series
    Dobre, Ioana A.
    Frank, Angela J.
    D'Silva, Kristin M.
    Christiani, David C.
    Okin, Daniel
    Sharma, Amita
    Montesi, Sydney B.
    CLINICAL LUNG CANCER, 2021, 22 (05) : E738 - E744
  • [2] Programmed cell death protein 1 (PD-1) in infection
    Leth, Steffen
    Jensen-Fangel, Soren
    APMIS, 2020, 128 (02) : 177 - 187
  • [3] COMPETING RISKS OF DEATH IN OLDER ADULTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) INHIBITORS
    Kim, Y.
    Suh, H. S.
    Park, C.
    VALUE IN HEALTH, 2024, 27 (06) : S40 - S40
  • [4] Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.
    Bassanelli, Maria
    Giannarelli, Diana
    Ricciuti, Biagio
    Magri, Valentina
    Cecere, Fabiana Letizia
    Roberto, Michela
    Giacinti, Silvana
    Barucca, Viola
    Cassese, Raffaele
    De Giglio, Andrea
    Scagnoli, Simone
    Milella, Michele
    Santarelli, Mario
    Bengala, Carmelo
    Ruggeri, Enzo Maria
    Marchetti, Paolo
    Cognetti, Francesco
    Gelibter, Alain
    Chiari, Rita
    Ceribelli, Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Justin C. Kao
    Adipong Brickshawana
    Teerin Liewluck
    Current Neurology and Neuroscience Reports, 2018, 18
  • [6] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Kao, Justin C.
    Brickshawana, Adipong
    Liewluck, Teerin
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (10)
  • [7] Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
    Bari, Shahla
    Muzaffar, Jameel
    Chan, Austin
    Jain, Sanjay R.
    Haider, Ahmad M.
    Curry, Marjorie Adams
    Hostler, Christopher J.
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [8] Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis
    Guo, Lijuan
    Lin, Xiaoyi
    Lin, Xin
    Wang, Yulei
    Lin, Jiali
    Zhang, Yi
    Chen, Xiangqing
    Chen, Miao
    Zhang, Guochun
    Zhang, Yifang
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (02): : 91 - 102
  • [9] PET Imaging of Programmed Cell Death Protein 1 (PD-1) in a Humanized Mouse Model of Lung Cancer
    Cai, W.
    Jiang, D.
    England, C. G.
    Barnhart, T. E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S144 - S145
  • [10] Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
    Abaza, Abdelrahman
    Idris, Faten Sid
    Shaikh, Humna Anis
    Vahora, Ilma
    Moparthi, Kiran Prasad
    Al Rushaidi, Majdah T.
    Muddam, Meghana Reddy
    Obajeun, Omobolanle A.
    Jaramillo, Arturo P.
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
12345